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     The BCR-ABL fusion oncoprotein accelerates differentiation and proliferation of 27 
myeloid cells during the chronic phase of chronic myeloid leukemia (CP-CML). Here, the 28 
role of C/EBPβ, a regulator for 'emergency granulopoiesis', in the pathogenesis of CP-CML 29 
was examined. C/EBPβ expression was upregulated in Lineage- CD34+ CD38- 30 
hematopoietic stem cells and myeloid progenitors isolated from bone marrow of patients 31 
with CP-CML. In EML cells, a mouse hematopoietic stem cell line, BCR-ABL upregulated 32 
C/EBPβ, at least in part, through the activation of STAT5. Myeloid differentiation and 33 
proliferation induced by BCR-ABL was significantly impaired in C/EBPβ-deficient bone 34 
marrow cells in vitro. Mice that were transplanted with BCR-ABL-transduced C/EBPβ 35 
knockout bone marrow cells survived longer than mice that received BCR-ABL-transduced 36 
wild-type bone marrow cells. Significantly higher levels of leukemic stem cells were 37 
maintained in BCR-ABL-transduced C/EBPβ-deficient cells than in BCR-ABL-transduced 38 
wild-type cells. These results suggest that C/EBPβ is involved in BCR-ABL-mediated 39 
myeloid expansion. Further elucidation of the molecular mechanisms underlying the 40 
C/EBPβ-mediated stem cell loss might reveal a novel therapeutic strategy for eradication of 41 
CML stem cells. 42 
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Chronic phase chronic myeloid leukemia (CP-CML) is characterized by massive 46 
proliferation and differentiation of myeloid cells.1, 2 In sharp contrast to acute myeloid 47 
leukemia with leukemic hiatus, both myeloid progenitors and mature granulocytes 48 
accumulate in the bone marrow, peripheral blood and spleen in CP-CML.1 The myeloid 49 
expansion in CP-CML has been attributed to the BCR-ABL fusion protein resulting from a 50 
translocation between chromosomes 9 and 22.2-4 Experiments using transgenic mouse 51 
models have shown that the BCR-ABL-mediated leukemic status is reversed by 52 
suppression of BCR-ABL,5-7 suggesting that BCR-ABL is the sole cause of the myeloid 53 
expansion in CP-CML. In practice, inhibition of the BCR-ABL tyrosine kinase activity 54 
effectively controls the disease during the chronic phase in most cases.8-12 Recent findings 55 
suggested a hierarchical organization of CML hematopoiesis, with CML stem cells giving 56 
rise to heterogeneous progeny.13-15 Accumulating clinical experiences, together with 57 
experimental data, have shown that leukemic stem cells in CP-CML are resistant to tyrosine 58 
kinase inhibitors (TKIs) and sometimes causes a relapse of the disease after discontinuation 59 
of TKI treatment.16-19 Progression of CML toward the accelerated phase and blast crisis is 60 
considered to be a consequence of further acquisition of genetic mutations, which makes 61 
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the disease more resistant to TKIs and results in an extremely poor prognosis.20, 21 62 
Therefore, a better understanding of the characteristics of leukemic stem cells, as well as 63 
the pathogenesis of CP-CML, are essential for establishing a novel therapeutic strategy for 64 
CML. 65 
     Granulopoiesis is a process in which hematopoietic stem cells give rise to mature 66 
granulocytes throughout life. Our previous findings revealed that a member of the 67 
CCAAT/enhancer binding protein (C/EBP) family of transcription factors, C/EBPβ, is 68 
required for 'emergency granulopoiesis', which is characterized by the accelerated 69 
differentiation and proliferation of granulocytic precursors in response to infections or 70 
cytokine stimulation.22 Myeloid expansion is a common feature of both emergency 71 
granulopoiesis and CP-CML. However, little is known regarding the role of C/EBPβ in the 72 
pathogenesis of CP-CML. In this study, the effects of BCR-ABL on the expression and 73 
function of C/EBPβ in BCR-ABL-induced myeloid expansion was determined and the 74 




Materials and methods 77 
Primary human bone marrow cells and cell lines 78 
Frozen samples of human bone marrow cells from healthy donors or untreated CP-CML 79 
patients were purchased from AllCells LLC (Emeryville, CA, USA). In all cases, written 80 
informed consent was obtained according to the Institutional Review Board or Human 81 
Subject Committee approved donor program. The characteristics of the patients are shown 82 
in Supplementary Table 1. EML cells 23 (a kind gift from Dr. Schickwann Tsai at the 83 
University of Utah, UT, USA) were maintained in Iscove modified Dulbecco’s medium 84 
(IMDM) supplemented with 20% heat-inactivated horse serum and 15% BHK/MKL 85 
cell-conditioned medium. 86 
 87 
Mice 88 
C57BL/6 mice were purchased from Clea Japan (Tokyo, Japan). C/EBPβ knockout (KO) 89 
mice 24 were back crossed to C57BL/6 strain mice at least 8 times. Whenever C/EBPβ KO 90 
mice were analyzed, wild-type (WT) littermates were used as control. All mice were 91 
maintained under specific pathogen-free conditions in the Institute of Laboratory Animals, 92 
Kyoto University. All experiments were performed according to the institutional guidelines 93 
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of Kyoto University. 94 
 95 
Reagents 96 
A STAT5 inhibitor (N’-((4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide) and 97 
Ly294002, a PI3K inhibitor, were purchased from Merck (Darmstadt, Germany). U0126, a 98 
MEK inhibitor, was purchased from Cell Signaling Technology (Danvers, MA, USA). 99 
Stock solutions of the STAT5 inhibitor, Ly294002, and U0126 were made in dimethyl 100 
sulfoxide (DMSO). 101 
 102 
Plasmids 103 
The pMSCVneo vector and pMSCV-internal ribosome entry site- green fluorescent protein 104 
(GFP) vector (MIG),25 and their derivatives for the expression of BCR-ABL (p210), were 105 
kind gifts from Dr. Keiko Okuda (Kyoto Prefectural University of Medicine, Kyoto, Japan). 106 
Retroviruses expressing the constitutively-active STAT5 mutant (STAT51*6) 26 and the 107 
dominant negative STAT5 mutant (STAT5∆749) 27 were kind gifts from Dr. Toshio Kitamura 108 




Retrovirus infection 111 
Plat-E packaging cells 28 were transfected with retrovirus vectors using FuGENE6 (Roche 112 
Diagnostics, Mannheim, Germany) as previously described.22, 28 Bone marrow cells were 113 
harvested from mice (4 to 8 weeks of age) treated with 5-fluorouracil (5-FU) (150 mg/kg, 114 
intraperitoneally). The bone marrow cells were cultured at 37 °C for 48 h in IMDM 115 
containing 15% FBS, 50 μM 2-mercaptoethanol, 50 ng/ml mouse stem cell factor (SCF), 116 
50 ng/ml human thrombopoietin (TPO) (a kind gift from Kyowa Hakko Kirin Co., Ltd), 50 117 
ng/ml mouse fms-like tyrosine kinase 3 ligand (FL), and 10 ng/ml mouse interleukin-6 118 
(IL-6). First round retroviral infection was carried out using RetroNectin (Takara Bio, Otsu, 119 
Japan) in the same medium. For the second round infection, polybrene was added with the 120 
retroviral supernatant.  121 
 122 
Bone marrow transplantation 123 
Recipient C57BL/6 mice (8 to 10 weeks of age) were lethally irradiated (10 Gy). MIG or 124 
MIG-BCR-ABL-transduced bone marrow cells (0.5 to 1 × 105 GFP-positive cells per 125 
mouse) were injected into the tail vein of primary recipient mice. For radioprotection, 2 × 126 
105 cells of freshly harvested whole bone marrow were co-transplanted. For secondary 127 
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transplantation, bone marrow cells were harvested from mice that received the primary 128 
transplants and 0.2 to 2 × 106 GFP-positive cells were intravenously injected into 129 
sublethally irradiated secondary recipient mice. The frequencies of leukemic stem cells 130 
were calculated using the L-Calc software (StemCell Technologies, Vancouver, Canada). 131 
 132 
Methylcellulose colony-forming assay 133 
MIG-BCR-ABL-transduced mouse bone marrow cells from C/EBPβ KO or WT mice were 134 
subjected to a methylcellulose colony-forming assay using the cytokine-free medium 135 
Methocult 3231 (StemCell Technologies). The fluorescence images of the colonies were 136 
obtained using AxioCam MRm digital camera and Axio Vision software in combination 137 
with SteREO Lumar V12 microscope and Neolumar S objective lens (0.8×) (Carl Zeiss, 138 
Oberkochen, Germany). 139 
 140 
Wright Giemsa staining 141 
Smears of mice peripheral blood or bone marrow cells and cytospin slides of EML cells or 142 
colony-forming cells were stained using a Diff-Quik kit (Sysmex, Kobe, Japan), a modified 143 
Wright Giemsa staining system. Images were obtained using DP71 digital camera and DP 144 
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Controller software in combination with CX41 microscope and PlanCN objective lens (40× 145 
/ 0.65 numerical aperture) (Olympus, Tokyo, Japan). 146 
 147 
Flow cytometric analysis 148 
Flow cytometric analysis and cell sorting were performed with a FACSCalibur, FACSCanto 149 
II, or FACSAria instrument (BD Biosciences, San Jose, CA, USA). As lineage markers for 150 
human bone marrow mononuclear cells, phycoerythrin (PE)-Cy5-conjugated anti-CD235, 151 
biotin-conjugated anti-CD3, CD4, CD8, CD11b, CD14, CD19, CD20 (eBioscience, San 152 
Diego, CA, USA), and anti-CD56 antibodies (Bio Legend, San Diego, CA, USA) were 153 
used and followed by staining with streptavidin-PE-Cy5. Cells were further stained with 154 
allophycocyanin (APC)-conjugated anti-CD34 (8G12), phycoerythrin (PE)-conjugated 155 
anti-CD38 (HIT2), fluorescein isothiocyanate (FITC)-conjugated anti-CD45RA (HI100) 156 
(all from BD Pharmingen, San Diego, CA, USA) and PE-Cy7-conjugated anti-CD123 157 
antibodies (eBioscience) for definition of hematopoietic stem cells and myeloid progenitors. 158 
For the staining of mouse cells, PerCP-Cy5.5-conjugated anti-CD3, CD4, CD11b, B220, 159 
and Ter119 antibodies, and PE-Cy5.5-conjugated anti-CD8 and Gr-1 antibodies (all from 160 
eBioscience) were used as lineage markers. PE-Cy7-conjugated anti-Sca-1, PE-conjugated 161 
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anti-CD11b and APC-conjugated anti-c-kit antibodies (all from eBioscience) were used for 162 
definition of hematopoietic stem cells and myeloid cells.  Data were analyzed with the 163 
FlowJo software (Tree Star, Ashland, OR, USA). 164 
 165 
Real-time RT-PCR 166 
Total RNA was extracted with an RNeasy Micro Kit (Qiagen, Valencia, CA, USA) and 167 
converted to cDNA using random primers. The cDNA was amplified using an Applied 168 
Biosystems Step One Plus thermal cycler. The following parameters were used: 95 °C for 169 
20 sec, followed by 45 cycles at 95 °C for 1 sec and 60 °C for 20 sec. The following 170 
primers, and probes from the Universal Probe Library (Roche Applied Science, Mannheim, 171 
Germany) were used: for mouse C/EBPβ, probe #55, and primers 172 
5′-ATCGACTTCAGCCCCTACCT-3′ and 5′-TAGTCGTCGGCGAAGAGG-3′; for mouse 173 
GAPDH, probe #80, and primers 5′-TGTCCGTCGTGGATCTGAC-3′ and 174 
5′-CCTGCTTCACCACCTTCTTG-3′; for human C/EBPβ, probe #74, and primers 175 
5′-CGCTTACCTCGGCTACCA-3′ and 5′-ACGAGGAGGACGTGGAGAG-3′; and for 176 
human GAPDH, probe #60, and primers 5′-AGCCACATCGCTCAGACAC-3′ and 177 





Western blot analysis 181 
Cells were diluted with equal amounts of Laemmli sample buffer and boiled at 100 °C for 182 
10 min. Samples were separated by SDS-PAGE and transferred to polyvinylidene fluoride 183 
membranes. A “Can Get” Signal immunoreactions enhancer kit (Toyobo, Osaka, Japan) 184 
was used to dilute the primary and secondary antibodies. Antibodies specific for C/EBPβ 185 
(sc-150, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and GAPDH (sc-25778, Santa 186 
Cruz Biotechnology) were used as primary antibodies. Immunoreactive proteins were 187 
detected using horseradish peroxidase-conjugated anti-rabbit IgG (NA934V, GE Healthcare, 188 




Statistical analyses were performed using Student’s t-test. Survival of mice was analyzed 193 






C/EBPβ is upregulated in bone marrow hematopoietic stem cells and myeloid 198 
progenitors from patients with CP-CML  199 
C/EBPβ expression is upregulated or maintained in normal myeloid progenitors 200 
during emergency granulopoiesis, while the expression of all other C/EBP family members 201 
was downregulated.22 Therefore, the expression of C/EBPβ in bone marrow cells of 202 
patients with CP-CML was examined. Among the lineage marker negative (Lin-) bone 203 
marrow cells, the frequency of CD34+ CD38- hematopoietic stem cells (HSCs) was lower 204 
and the frequency of CD34+ CD38+ myeloid progenitors was higher in CP-CML bone 205 
marrow than in bone marrow from healthy donors (Figure 1a and b, Supplementary Figure 206 
S1). The CD34+ CD38+ population was further subdivided into common myeloid 207 
progenitors (CMPs), granulocyte-macrophage progenitors (GMPs), and 208 
megakaryocyte-erythrocyte progenitors (MEPs) based on the expression levels of CD123 209 
and CD45RA 29 (Figure 1a). The frequency of GMPs was significantly lower and that of 210 
MEPs was significantly higher (approximately two-fold) in CP-CML bone marrow than in 211 
bone marrow from healthy donors (Figure 1c). The differences between normal and 212 
CP-CML bone marrow in the frequency of CD34+ CD38- HSCs and of myeloid progenitors 213 
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were consistent with previous findings.13, 15, 30 The expression of C/EBPβ in the purified 214 
progenitors was measured. The levels of C/EBPβ mRNA in HSCs and all the myeloid 215 
progenitors from CP-CML bone marrow were significantly higher than levels in bone 216 
marrow from healthy donors (Figure 1d, healthy donors, n = 6; CP-CML, n = 5; GMP, P < 217 
0.01; HSC, CMP, and MEPs, P < 0.05). These results suggest that C/EBPβ is upregulated in 218 
HSCs and myeloid progenitors in patients with CP-CML. 219 
 220 
BCR-ABL upregulates C/EBPβ in EML cells, a mouse hematopoietic stem cell line  221 
 The presence of the BCR-ABL fusion protein is thought to be the only difference 222 
between normal hematopoiesis and BCR-ABL-mediated myeloid expansion in CP-CML.2, 4 223 
To assess whether BCR-ABL could upregulate C/EBPβ, the BCR-ABL gene was 224 
retrovirally introduced into a factor-dependent mouse hematopoietic stem cell line, EML 225 
cells, and the expression of C/EBPβ was compared with EML cells transduced with a 226 
control vector (EML-control). After transduction with BCR-ABL, EML cells 227 
(EML-BCR-ABL) became factor-independent and could be cultured long term in the 228 
absence of stem cell factor-containing conditioned medium. The morphologies of the 229 
EML-control and EML-BCR-ABL cells were indistinguishable by Giemsa staining (Figure 230 
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2a, Day 0).  The parent EML cells expressed c-kit but not CD11b. Flow cytometric 231 
analysis of the transduced cells revealed that a small subset of EML-BCR-ABL expressed 232 
c-kit at a slightly lower intensity and expressed CD11b weakly (Figure 2b, Day 0). Myeloid 233 
differentiation of EML cells can be induced by the addition of interleukin-3, retinoic acid, 234 
and granulocyte-macrophage colony stimulating factor (GM-CSF).23 As shown in Figure 2a 235 
(Day 5), myeloid differentiation of both EML-control and EML-BCR-ABL cells was 236 
effectively induced. Lower c-kit and higher CD11b expression by EML-control cells was 237 
observed 5 days after the induction of differentiation and the extent of the changes in the 238 
expression of c-kit and CD11b was more evident in EML-BCR-ABL cells (Figure 2b). 239 
These results suggest that BCR-ABL enhanced myeloid differentiation of immature cells 240 
such as EML cells.  241 
 The amount of C/EBPβ mRNA in undifferentiated EML-BCR-ABL cells was 242 
1.87-fold higher than in undifferentiated EML-control cells (Figure 2c). When the c-kit+ 243 
CD11b- fraction of the EML-control cells and EML-BCR-ABL cells was analyzed, a 244 
significant difference was still observed 2.26-fold higher in EML-BCR-ABL cells (Figure 245 
2d), suggesting that the upregulation of C/EBPβ was not the result of contamination of 246 
differentiated cells. The level of C/EBPβ protein was 3.76-fold higher in EML-BCR-ABL 247 
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cells relative to EML-control cells (Figure 2e). When EML-BCR-ABL cells were treated 248 
with imatinib mesylate, the upregulation of C/EBPβ by BCR-ABL was reduced (Figure 2f), 249 
while the level of C/EBPβ in EML-control cells was not affected. These results suggest that 250 
C/EBPβ is upregulated directly in response to signaling downstream of BCR-ABL. 251 
 252 
STAT5 is involved in the BCR-ABL-mediated upregulation of C/EBPβ 253 
 Various signaling pathways are activated by BCR-ABL, including the JAK/STAT, 254 
Raf/MEK/ERK, and PI3K/AKT pathways.31-36 To elucidate the signaling pathways 255 
responsible for the upregulation of C/EBPβ, each of the known downstream signaling 256 
pathways was inhibited. When EML-BCR-ABL cells were treated with the MEK inhibitor 257 
U0126 or the PI3K inhibitor Ly294002, C/EBPβ expression was not affected (Figure 3a). In 258 
contrast, treatment with the STAT5 inhibitor 259 
(N’-((4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide) significantly reduced 260 
C/EBPβ expression in EML-BCR-ABL cells (Figure 3b).  A dominant negative STAT5 261 
mutant, STAT5∆749, was introduced into the EML-derived cell lines to inhibit STAT5. 262 
STAT5∆749 significantly repressed the expression of C/EBPβ in EML-BCR-ABL cells but 263 
had no effect in EML-control cells (Figure 3c). Conversely, when a constitutively-active 264 
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STAT5 mutant, STAT51*6, was retrovirally transduced into the parental EML cells 265 
(EML-CA-STAT5), C/EBPβ mRNA levels were significantly greater compared to the level 266 
in EML cells transduced with a control vector (Figure 3d). These results suggest that 267 
STAT5 is involved in the BCR-ABL-mediated upregulation of C/EBPβ.   268 
 269 
C/EBPβ regulates BCR-ABL-mediated proliferation and differentiation of myeloid 270 
cells in vitro 271 
The upregulation of C/EBPβ in the presence of BCR-ABL was confirmed using 272 
primary bone marrow cells. BCR-ABL was retrovirally introduced into bone marrow cells 273 
obtained from 5-FU-treated WT mice and RNA was extracted from purified c-kit+ Sca-1+ 274 
Lin- (KSL) cells after the transduced cells were cultured for 2 days. The RNA was analyzed 275 
by quantitative RT-PCR. The expression of C/EBPβ in BCR-ABL-transduced KSL cells 276 
was significantly greater than in control vector-transduced KSL cells (n = 3 each, P < 0.01) 277 
(Figure 4a). 278 
 To understand the role of C/EBPβ in BCR-ABL-mediated myeloid expansion, 279 
BCR-ABL and GFP were retrovirally introduced into bone marrow cells obtained from 280 
5-FU-treated C/EBPβ KO mice and their properties were compared to 281 
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BCR-ABL-transduced bone marrow cells from WT mice. The transduced cells were first 282 
subjected to cytokine-free semisolid methylcellulose culture. All the colonies formed on 283 
day 7 were GFP-positive and the numbers of colonies were equivalent between transduced 284 
bone marrow cells from WT and KO mice (Figure 4b and c), suggesting that the 285 
frequencies of clonogenic progenitors were similar. The majority of C/EBPβ KO 286 
cell-derived colonies were smaller in size (Figure 4b) and the cell number per C/EBPβ KO 287 
cell colony was significantly lower than WT cell colonies (P < 0.01) (Figure 4d). These 288 
findings suggest that the loss of C/EBPβ impaired BCR-ABL-mediated cell proliferation. 289 
Having observed a difference between WT and C/EBPβ KO cells in proliferative capacity 290 
in the presence of the BCR-ABL fusion protein, the morphologies of the colony-forming 291 
cells were assessed by Giemsa staining (Figure 4e). The BCR-ABL-transduced C/EBPβ 292 
KO cell colonies contained more immature myeloid cells with larger nuclei and basophilic 293 
cytoplasm, whereas the BCR-ABL-transduced WT cell colonies contained more mature 294 
neutrophilic granulocytes and macrophages (Figure 4e). Flow cytometric analysis revealed 295 
that the BCR-ABL-transduced C/EBPβ KO cells gave rise to a significantly higher 296 
proportion of c-kit+ cells and a lower proportion of CD11b+ cells, relative to 297 
BCR-ABL-transduced WT cells (%c-kit+ cells = 6.7 ± 1.0% vs. 2.0 ± 0.2%, P = 298 
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0.01; %CD11b+ cells = 17.9 ± 4.4% vs. 41.3 ± 8.8%, P = 0.039) (Figure 4f and g). In 299 
addition, BCR-ABL-transduced C/EBPβ KO cells-derived colonies could be replated more 300 
than three times in cytokine-free medium, whereas BCR-ABL-transduced WT cells stopped 301 
growing after being replated only twice (Figure 4h and Supplementary Figure S2). These 302 
results suggest that the C/EBPβ deficiency abolished the BCR-ABL-mediated proliferation 303 
and differentiation of myeloid cells. 304 
 305 
Loss of C/EBPβ delays BCR-ABL-mediated myeloid expansion in vivo 306 
 BCR-ABL-transduced bone marrow cells from C/EBPβ KO mice or WT mice 307 
were transplanted into lethally irradiated recipient mice to clarify the role of C/EBPβ in the 308 
in vivo myeloproliferation induced by BCR-ABL. After transplantation of transduced cells, 309 
increases in neutrophilic granulocytes were observed in the peripheral blood of mice having 310 
received either WT cells or KO cells (Figure 5a). Flow cytometric analysis of peripheral 311 
blood also revealed that over 70% of nucleated cells were CD11b+ in both WT and KO 312 
transplant recipients (Figure 5b). In mice transplanted with BCR-ABL-transduced C/EBPβ 313 
KO cells, the increase in white blood cell count (Figure 5c) and the development of 314 
splenomegaly (Figure 5d) were delayed compared to mice receiving transplants of WT 315 
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BCR-ABL-transduced cells. The median survival of mice transplanted with 316 
BCR-ABL-transduced WT cells was 19 days. In contrast, the median survival of mice 317 
transplanted with BCR-ABL-transduced C/EBPβ KO cells was 31 days, significantly 318 
longer than mice receiving transplants of BCR-ABL-transduced WT cells (P = 0.0005) 319 
(Figure 5e). These results suggest that C/EBPβ is involved in BCR-ABL-induced enhanced 320 
myelopoiesis in vivo. 321 
 322 
BCR-ABL-induced loss of self-renewing hematopoietic/leukemic stem cells was 323 
attenuated in the absence of C/EBPβ 324 
 In vitro experiments revealed that C/EBPβ KO bone marrow cells retained more 325 
c-kit+ immature cells and could be replated more times after transduction with BCR-ABL 326 
(Figure 4f-h, Supplementary Figure S2), suggesting that C/EBPβ is involved in the 327 
BCR-ABL-mediated loss of self-renewing hematopoietic/leukemic stem cells. Consistent 328 
with these observations, BCR-ABL-transduced C/EBPβ KO cells had given rise to a higher 329 
proportion of c-kit+ cells than BCR-ABL-transduced WT cells on day 19 after 330 
transplantation (16.0 ± 2.6% vs. 5.5 ± 4.6%, P = 0.01) (Figure 6a and b).  331 
 Serial transplantation experiments were carried out to determine the role of 332 
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C/EBPβ in the loss of self-renewal capacity. When 2 × 106 GFP+ bone marrow cells from 333 
the primary recipients were transplanted into sublethally irradiated secondary recipients, all 334 
the mice having received either BCR-ABL-transduced WT cells or BCR-ABL-transduced 335 
KO cells developed a myeloproliferative status, reminiscent of the first transplantation 336 
(Figure 6c). After transplantation of 1 × 106 GFP+ bone marrow cells from the primary 337 
transplant recipients, one of the four recipient mice that received a secondary transplant of 338 
BCR-ABL-transduced WT cells developed a myeloproliferative status and four out of five 339 
recipient mice that received a secondary transplant of BCR-ABL-transduced C/EBPβ KO 340 
cells developed a myeloproliferative disorder (Figure 6d). On day 38 after the secondary 341 
transplantation of 1 × 106 GFP+ bone marrow cells, BCR-ABL-transduced C/EBPβ KO 342 
cells achieved a significantly higher degree of chimerism in the peripheral blood of the 343 
secondary recipients than BCR-ABL-transduced WT cells (n = 8 each, P = 0.013) (Figure 344 
6e). None of the mice that received less than 0.5 x 106 GFP+ bone marrow cells from the 345 
primary recipients developed a myeloproliferative status. Based on these transplantation 346 
experiments, the estimated frequencies of leukemia-initiating cells in bone marrow of 347 
primary recipient mice transplanted with BCR-ABL-transduced WT cells and 348 
BCR-ABL-transduced C/EBPβ KO cells were 1 in 1 404 129 and 1 in 683 773, 349 
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respectively (Figure 6f). These results suggest that enhanced C/EBPβ expression induced 350 





     Proliferation and differentiation of myeloid cells are unique to CP-CML. This is the 354 
first report demonstrating that the BCR-ABL-mediated myeloid expansion in CP-CML is 355 
promoted by C/EBPβ, a regulator of 'emergency granulopoiesis'. 356 
     One of the major findings of this study is the upregulation of C/EBPβ by BCR-ABL 357 
in CP-CML. In EML cells or in immature mouse hematopoietic cells, BCR-ABL 358 
upregulated C/EBPβ and accelerated the differentiation of these cells (Figure 2b-e and 359 
Figure 4a). In contrast, previous reports showed that, in 32Dcl3 cells transduced with 360 
BCR-ABL, C/EBPβ was downregulated and granulocytic differentiation was blocked.37, 38 361 
One explanation for the discrepancy between the observations in EML cells and 32Dcl3 362 
cells may be due to the differentiation status. 32Dcl3 cells give rise only to neutrophilic 363 
granulocytes in the presence of G-CSF,39 while EML cells are multipotent and can give rise 364 
to monocytic, erythroid and lymphoid lineages, in addition to the granulocytic lineage,23 365 
suggesting that EML cells represent more immature hematopoietic cells than 32Dcl3 cells. 366 
The higher C/EBPβ expression in 32Dcl3 than in EML cells (Supplementary Figure S3) 367 
also supports this idea, as C/EBPβ is upregulated during myeloid differentiation.40, 41 368 
Taking into account the previous findings that HSCs are the target cell population for 369 
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BCR-ABL during chronic phase,4 the data from EML cells are most likely to reflect 370 
conditions of CP-CML. Consistent with our observations, Minami et al. found that C/EBPβ 371 
is one of the markedly upregulated genes in a pluripotent hematopoietic cell line transduced 372 
with BCR-ABL.42 Most importantly, C/EBPβ is upregulated in purified HSCs and myeloid 373 
progenitors obtained from patients with CP-CML, as shown in Figure 1d. The differences 374 
in BCR-ABL-mediated regulation of C/EBPβ in EML cells and in 32Dcl3 cells also 375 
suggested the involvement of cell context-dependent machinery. Guerzoni et al. described a 376 
downregulation of C/EBPβ associated with the progression of CML toward a blast crisis,37 377 
whereas our study focused on the upregulation of C/EBPβ in the chronic phase. The 378 
changes in the BCR-ABL-mediated regulation of C/EBPβ during the progression of CML 379 
may be a consequence of genetic or epigenetic changes, which result in a cell context 380 
similar to 32Dcl3 cells, in terms of the regulation of C/EBPβ. 381 
   BCR-ABL activates a number of signaling cascades through its tyrosine kinase activity. 382 
STAT5 is a well known target of BCR-ABL. STAT5 is phosphorylated by JAK2 43 and is 383 
thought to activate target genes to induce or maintain CP-CML.33, 44 Our current data 384 
strongly suggest that C/EBPβ resides downstream of STAT5. Transplantation of 385 
BCR-ABL-transduced STAT5 KO bone marrow cells resulted in delayed progression of a 386 
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myeloproliferative disorder in mice,33 a phenotype highly similar to our CP-CML model 387 
using C/EBPβ KO cells. The similarities between the behavior of BCR-ABL-transduced 388 
STAT5 KO cells and BCR-ABL-transduced C/EBPβ KO cells strongly suggested that these 389 
two molecules act sequentially in the same pathway. STAT5 and C/EBPβ are both essential 390 
for cytokine-induced granulopoiesis,22, 45-47 suggesting that STAT5 and C/EBPβ may also 391 
interact when emergency granulopoiesis is stimulated.  There has been no evidence, thus 392 
far, to demonstrate that STAT5 directly regulates C/EBPβ. The consensus binding site for 393 
STAT5 (TTCN3GAA) is not found in the proximal promoter region of C/EBPβ. Recently, 394 
Zhang et al. showed that STAT3 regulates C/EBPβ transcription through binding to the IL-6 395 
response element II (CTGGGA) located at -1180 base pairs in the C/EBPβ promoter.48 396 
However, our preliminary analysis of the 2000 base pairs proximal promoter region of 397 
C/EBPβ by reporter assay failed to identify the positive regulatory elements which respond 398 
to STAT5 (data not shown). In addition, specific binding of STAT5 to the particular 399 
regulatory element was not observed in published chromatin immunoprecipitation 400 
sequencing data analyzing T cells stimulated with interleukin-2 (GSE12346 (ref. 49) and 401 
GSE26553 (ref. 50)). These data suggest that STAT5 might upregulate C/EBPβ through 402 
binding to regulatory elements outside this IL-6 response element II or through other 403 
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indirect mechanisms. Elucidation of the direct or indirect interactions between STAT5 and 404 
C/EBPβ is necessary for further understanding of BCR-ABL-mediated myeloid expansion 405 
and emergency granulopoiesis. 406 
     Our present data showed that myeloid expansion was delayed when BCR-ABL was 407 
transduced into C/EBPβ KO bone marrow cells, clearly suggesting the involvement of 408 
C/EBPβ in the enhanced myelopoiesis observed in patients with CP-CML. The effects of 409 
BCR-ABL on the self-renewing potential of HSCs are still controversial. Schemionek et al 410 
recently reported that BCR-ABL partially impaired long term HSCs.51 In the present study, 411 
a phenotypically and functionally immature status was maintained in a greater fraction of 412 
BCR-ABL-transduced C/EBPβ KO cells than in BCR-ABL-transduced WT cells both in 413 
vitro and in vivo. These data suggested that C/EBPβ is involved in the BCR-ABL-mediated 414 
loss of self-renewing potential of the HSCs. From the therapeutic point of view, repression 415 
of C/EBPβ in CP-CML patients would delay the progression of the disease, although 416 
leaving leukemic stem cells relatively intact. This strategy might be effective for patients 417 
with BCR-ABL mutations that are resistant to tyrosine kinase inhibitors, as the role of 418 
C/EBPβ in the pathogenesis of CP-CML should be common to all BCR-ABL mutants. 419 
Alternatively, upregulation of C/EBPβ in leukemic stem cells might induce exhaustion of 420 
28 
 
the leukemic stem cells, leading to a complete cure for the disease. Actually, Guerzoni et al. 421 
showed that transduction of C/EBPβ promotes differentiation of BCR-ABL expressing 422 
cells.37, 52 The effects of upregulation of endogenous C/EBPβ on leukemic stem cells should 423 
be determined in the future. Further understanding of the regulation of the self-renewal and 424 
differentiation of leukemic stem cells in CP-CML may lead to identification of novel 425 
therapies for CML based on the regulation of C/EBPβ. 426 
     The leukocytosis observed during infections (=emergency granulopoiesis) is 427 
sometimes called a 'leukemoid' reaction because of the great increase in the number of 428 
myeloid cells with a 'left shift' in the shape of the nucleus.53 Here, a molecular link between 429 
leukemoid reactions and CP-CML was identified. C/EBPβ fine tunes the proliferation and 430 
differentiation of HSCs and CML leukemic stem cells in response to their respective 431 
upstream signals. Further elucidation of the molecular mechanisms that regulate the 432 
self-renewal and differentiation of stem cells in CP-CML and emergency granulopoiesis 433 
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Figure Legends 667 
Figure 1. C/EBPβ expression in hematopoietic stem and progenitor cells from the bone 668 
marrow of CP-CML patients.  669 
(a) Flow cytometric analysis of lineage marker negative (Lin-) bone marrow cells from 670 
healthy donors and CP-CML patients identified CD34+ CD38- hematopoietic stem cells 671 
(HSC) and CD34+ CD38+ myeloid progenitors (upper panels). Myeloid progenitors were 672 
further subdivided into common myeloid progenitors (CMP), granulocyte-macrophage 673 
progenitors (GMP) and megakaryocyte-erythrocyte progenitors (MEP) based on the 674 
expression of CD45RA and CD123 (lower panels). The data shown are representative of six 675 
independent experiments. (b) Frequency of CD34+ CD38- HSCs within the Lin− fraction of 676 
bone marrow cells. Error bars indicate SD (healthy donors, n = 6; CP-CML, n = 5; *P < 677 
0.05). (c) Percentage of CMPs, GMPs, and MEPs in the Lin- CD34+ CD38+ fraction. Error 678 
bars indicate SD (healthy donors, n = 6; CP-CML, n = 5; *P < 0.001). (d) C/EBPβ mRNA 679 
levels in purified HSCs, CMPs, GMPs, and MEPs. Results were normalized to the 680 
expression level of HSCs from healthy donors (healthy donors, n = 6; CP-CML, n = 5; *P < 681 




Figure 2. Effects of BCR-ABL on the expression of C/EBPβ in EML cells.  684 
(a) Wright Giemsa staining of pMSCVneo vector-transduced EML cells (EML-control) and 685 
BCR-ABL-containing pMSCVneo vector-transduced EML cells (EML-BCR-ABL) before 686 
(Day 0) and after (Day 5) the induction of myeloid differentiation (scale bar, 20 μm; 687 
original magnification, 400×). (b) Flow cytometric analysis of c-kit and CD11b expression 688 
in EML-control and EML-BCR-ABL cells (Day 0 and Day 5 after myeloid differentiation). 689 
Numbers in each quadrant indicate the percentage of live cells. (c) C/EBPβ mRNA levels in 690 
EML-control and EML-BCR-ABL cells. Results were normalized to the expression level of 691 
control. Error bars indicate SD from duplicate samples. Results are representative of three 692 
independent experiments. *P = 0.011. (d) C/EBPβ mRNA levels in c-kit+ CD11b- fraction 693 
of the EML-control cells and EML-BCR-ABL cells. Results were normalized to the 694 
expression level of control. Error bars indicate SD from duplicate samples. *P < 0.01. (e) 695 
C/EBPβ protein levels in EML-control and EML-BCR-ABL cells. Results were normalized 696 
to the expression level of control. Error bars indicate SD from duplicate samples. Results 697 
are representative of three independent experiments. *P < 0.01. (f) C/EBPβ mRNA levels 698 
in EML-control and EML-BCR-ABL cells with or without a 48 h treatment with imatinib 699 
mesylate (100 nM). Dimethyl sulfoxide (DMSO) was used as the control. Results were 700 
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normalized to the expression level of control. Error bars indicate SD from duplicate 701 
samples. Results are representative of three independent experiments. *P = 0.016.  702 
 703 
Figure 3. Involvement of BCR-ABL downstream signaling pathways in the upregulation of 704 
C/EBPβ.  705 
Changes in C/EBPβ mRNA in EML-BCR-ABL cells 24 h after treatment with the PI3K 706 
inhibitor Ly294002 (2.5 μM), the MEK inhibitor U0126 (25 μM) (a), or a STAT5 inhibitor 707 
(40 μM) (b). DMSO was used as the control. Results were normalized to the expression 708 
level of control. Error bars indicate SD from duplicate samples. Results are representative 709 
of two independent experiments. *P < 0.01. (c) C/EBPβ mRNA in EML-control and 710 
EML-BCR-ABL cells transduced with a dominant negative STAT5 mutant, STAT5∆749. 711 
Results were normalized to the expression level of control. Error bars indicate SD from 712 
duplicate samples. Results are representative of two independent experiments. *P < 0.05. 713 
(d) C/EBPβ mRNA levels in EML cells transduced with a constitutively-active STAT5 714 
mutant (CA-STAT5: STAT51*6) or empty-vector. Results were normalized to the expression 715 
level of control. Error bars indicate the SD from duplicate samples. Results are 716 




Figure 4. BCR-ABL-mediated in vitro colony formation in the absence of C/EBPβ.  719 
(a) C/EBPβ mRNA levels in c-kit+ Sca-1+ Lin- cells from WT bone marrow cells 720 
transduced with a control MIG vector or a MIG-BCR-ABL vector (n = 3 each, P < 0.01). 721 
(b) Colonies formed by BCR-ABL-transduced C/EBPβ KO bone marrow cells and WT 722 
bone marrow cells after culture for 7 days in cytokine-free methylcellulose (scale bar, 1 723 
mm). Colony numbers (c), cell numbers per colony (d), and Wright Giemsa staining (scale 724 
bar, 20 μm; original magnification, 400×) (e) of the colony-forming cells are shown. Error 725 
bars indicate SD from triplicate cultures. Results are representative of three independent 726 
experiments. *P < 0.01. (f) Flow cytometric analysis of the cells forming primary colonies 727 
by day 7. Numbers in each quadrant indicate the percentage of live cells. (g) Frequency of 728 
c-kit+ cells and CD11b+ cells in the cells forming primary colonies by day 7. Results are 729 
representative of two independent experiments. *P < 0.05. (h) Serial colony-replating of 1 730 
× 104 BCR-ABL-transduced C/EBPβ WT and KO bone marrow cells. The colonies were 731 
counted and collected on day 10 (2nd) or 14 (3rd), respectively. Error bars indicate SD 732 
from triplicate cultures. Results are representative of three independent experiments. *P < 733 




Figure 5. C/EBPβ deficiency alters the BCR-ABL-dependent myeloproliferative status in 736 
vivo.  737 
Wright Giemsa staining (scale bar, 20 μm; original magnification, 400×) (a), 20 days 738 
post-transplantation, and flow cytometric analysis (b), 28 days post-transplantation, of 739 
peripheral blood from recipient mice transplanted with BCR-ABL-transduced WT cells or 740 
BCR-ABL-transduced C/EBPβ KO cells. Numbers in quadrants indicate the percentages 741 
within peripheral blood nucleated cells. (c) Peripheral white blood cell count of recipients 742 
after transplantation. Data are mean ± SD (n = 4 each; *P < 0.05). (d) Splenomegaly 743 
observed in recipients at day 19 after transplantation (scale bar, 10 mm). Spleen weights are 744 
presented as mean ± SD (WT, n = 9; KO, n = 6; *P < 0.01). (e) Survival of recipients 745 
transplanted with BCR-ABL-transduced WT cells or BCR-ABL-transduced C/EBPβ KO 746 
cells (WT, n = 12; KO, n = 11; *P = 0.0005).  747 
 748 
Figure 6. Involvement of C/EBPβ in BCR-ABL-mediated loss of immature hematopoietic 749 
cells.  750 
Flow cytometric analysis of GFP+ bone marrow cells from recipients 19 days after 751 
49 
 
transplantation of BCR-ABL-transduced WT cells or BCR-ABL-transduced C/EBPβ KO 752 
cells (a and b). Numbers in quadrants indicate the percentages within GFP+ bone marrow 753 
cells (WT, n = 2; KO, n = 3; *P = 0.01). (c and d) Survival of secondary transplantation 754 
recipients. 2 × 106 (c; WT, n = 7; KO, n = 7) or 1 × 106 BCR-ABL-transduced GFP+ cells 755 
(d; WT, n = 4; KO, n = 5) from the first recipients were transplanted. (e) GFP+ cell 756 
chimerism on day 38 after the secondary transplantation of BCR-ABL-transduced WT cells 757 
or BCR-ABL-transduced C/EBPβ KO cells (n = 8 each; *P = 0.013).  (f) The frequencies 758 
of leukemia-initiating cells in bone marrow of primary recipient mice transplanted with 759 
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Supplementary Figure Legend 
Figure S1. Frequency of myeloid progenitors in bone marrow of healthy donors and 





 myeloid progenitors within the Lin
 
fraction of bone 
marrow cells. Error bars indicate SD (healthy donors, n = 6; CP-CML, n = 5; *P  
0.05). 
 
Figure S2. BCR-ABL-transduced C/EBP KO cells could be replated at least up to 5 
times. 
Serial colony-replating of 1 × 10
4
 BCR-ABL-transduced C/EBP WT and KO bone 
marrow cells. The colonies were counted and collected on day 10 (2nd) or 14 (3rd, 4th, 
and 5th), respectively. Error bars indicate SD from triplicate cultures. 
 
Figure S3. C/EBP expression in EML cells and 32Dcl3 cells. 
C/EBP mRNA levels in EML cells and 32Dcl3 cells. Results were mean values of two 
independent experiments and normalized to the expression level of EML cells. Error bar 






















































































147742 M / 42 Asian CP No 16.1 3.68 121 98 
06-620 F / 66 Caucasian CP No 155.6 3.08 100 1147 
2008032001 NA Caucasian CP No NA NA NA NA 
EBO-BM0129 M / NA Asian CP No 76.8 4.03 112 1116 
160568 M / NA Asian CP No NA NA NA NA 
 
CP, chronic phase; WBC, white blood cells; RBC, red blood cells; HGB, hemoglobin; 
PLT, platelet. NA indicates not available. 
 
